Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on OutcomeShow More
Clinical Lymphoma Myeloma and Leukemia , Volume 11, pp 44-49; doi:10.3816/clml.2011.n.005
The publisher has not yet granted permission to display this abstract.
Keywords: safety / multiple myeloma / Efficacy / doxorubicin / PEGylated / plus Bortezomib / PLD plus / outcomes over bortezomib
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Click here to see the statistics on "Clinical Lymphoma Myeloma and Leukemia" .